GSK Inks Up to $750M Deal to Expand Myeloma Pipeline
GSK sits 28% above its 52-week low of $39.29.
Summary
GSK is expanding its multiple myeloma pipeline through a deal worth up to $750 million. The agreement adds new assets to its oncology portfolio, reinforcing its commitment to blood cancers. This follows a series of positive pipeline developments, including FDA approvals for Jideytro and Utebzi, and the successful completion of its £2 billion buyback. The deal is modest relative to GSK's market cap but signals continued investment in high-value oncology areas. Specific terms and the partner's identity are not disclosed in the headline.
At the time of this announcement, GSK was trading at $50.11 on NYSE in the Life Sciences sector, with a market capitalization of approximately $100.3B. The 52-week trading range was $39.29 to $61.70. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.